Ensysce Biosciences (ENSC) Issues Mid-Year 2024 Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. KNX
10. QGEN

Go back to Ensysce Biosciences (ENSC) Issues Mid-Year 2024 Update

Ensysce Biosciences Provides Mid-Year 2024 Update

July 23, 2024 10:32 AM EDT

~ Ready to Commence PF614 Phase 3 Clinical Trial in 2024 ~

~ Continued Clinical Development of Overdose Protection Breakthrough Therapy ~

~ Identified Lead Clinical Candidate for Opioid Use Disorder Program ~

SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today provides a Company review and update on a successful first half of 2024, including achievement of Breakthrough... More